Apixaban is one of the new oral anticoagulants, which is prescribed as an alternative to
vitamin K antagonists (VKAs). Concerns regarding its bleeding profile persist and require …

Aims There are concerns regarding increased risk of acute coronary syndrome with
dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban …

Background Bleeding is a complication of treatment with factor Xa inhibitors, but there are no
specific agents for the reversal of the effects of these drugs. Andexanet is designed to …

Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical
development for the prevention and treatment of thromboembolic diseases. Apixaban was …

Background: Apixaban is a direct oral anticoagulant, which inhibits factor Xa. It has
demonstrated clinical efficacy in prevention of stroke and systemic embolism in adult …

Abstract Background In the ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and≥ 2 dose …

Anticoagulation with heparin and vitamin K antagonist has been the mainstay of prevention
and treatment of venous thromboembolism (VTE) for many years. In recent years, novel oral …

Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective
and safe antithrombotic treatments are a public health priority. New antithrombotics such as …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Anticoagulant drugs have an essential role in the prevention and treatment of
thromboembolic diseases. Currently available anticoagulants substantially reduce the …